Media coverage about Flex Pharma (NASDAQ:FLKS) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flex Pharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.9613172778523 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Flex Pharma (NASDAQ FLKS) opened at $4.38 on Monday. Flex Pharma has a one year low of $2.68 and a one year high of $5.93. The stock has a market cap of $78.36, a price-to-earnings ratio of -2.17 and a beta of 3.54.

Flex Pharma (NASDAQ:FLKS) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.06. Flex Pharma had a negative net margin of 2,655.19% and a negative return on equity of 71.39%. The company had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.47 million. research analysts predict that Flex Pharma will post -2.33 earnings per share for the current year.

Several equities research analysts have issued reports on FLKS shares. Zacks Investment Research cut shares of Flex Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Roth Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Flex Pharma in a research note on Wednesday, January 3rd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $10.00 target price on shares of Flex Pharma in a research note on Wednesday, January 17th. Finally, Ladenburg Thalmann Financial Services started coverage on shares of Flex Pharma in a research note on Thursday. They set a “buy” rating and a $12.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $9.79.

TRADEMARK VIOLATION WARNING: This report was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2018/01/29/flex-pharma-flks-getting-somewhat-favorable-press-coverage-study-finds.html.

About Flex Pharma

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Insider Buying and Selling by Quarter for Flex Pharma (NASDAQ:FLKS)

Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.